Gorin Michael A, Marashdeh Wael, Ross Ashley E, Allaf Mohammad E, Pienta Kenneth J, Pomper Martin G, Rowe Steven P
aDepartment of Urology, The James Buchanan Brady Urological Institute bThe Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Nucl Med Commun. 2017 Sep;38(9):795-798. doi: 10.1097/MNM.0000000000000716.
PET imaging using radiotracers that target prostate-specific membrane antigen (PSMA) are increasingly being used in the evaluation of men with prostate cancer (PCa). It is therefore of increasing importance for imaging specialists to recognize potential pitfalls of this novel imaging technique. In this report, we describe a series of benign elastofibroma dorsi with uptake of the PSMA-targeted PET radiotracer F-DCFPyL.
We retrospectively analyzed the imaging data of 75 men with PCa who were consecutively imaged with F-DCFPyL PET/CT. Acquired images were reviewed for the presence of radiotracer uptake in the region of the scapular tip adjacent to the chest wall. Only those lesions with discrete radiotracer uptake corresponding to an area on CT with the characteristic appearance of an elastofibroma were considered positive.
In total, 18/75 (24.0%) patients had evidence of at least one elastofibroma dorsi on F-DCFPyL PET/CT. Eight (44.4%) of these patients had unilateral lesions, all of which were right sided. Detected lesions had a median maximal diameter of 2.3 cm (range: 1.3-8.4 cm) and a median perpendicular thickness to the chest wall of 0.9 cm (range: 0.6-2.5 cm). The median maximum standardized uptake value of detected lesions was 1.4 (range: 1.1-2.4) and the median maximum standardized uptake value corrected to lean body mass was 1.1 (range: 0.8-1.7).
This study is the first to report uptake of a PSMA-targeted PET radiotracer in elastofibroma dorsi. Radiotracer uptake in these benign lesions should not be falsely mistaken as sites of metastatic PCa.
使用靶向前列腺特异性膜抗原（PSMA）的放射性示踪剂进行正电子发射断层扫描（PET）成像，越来越多地用于前列腺癌（PCa）男性患者的评估。因此，对于影像专家来说，认识到这种新型成像技术的潜在陷阱变得越来越重要。在本报告中，我们描述了一系列摄取PSMA靶向PET放射性示踪剂F-DCFPyL的背部良性弹力纤维瘤。
我们回顾性分析了75例连续接受F-DCFPyL PET/CT成像的PCa男性患者的影像数据。对获取的图像进行检查，查看肩胛尖与胸壁相邻区域是否有放射性示踪剂摄取。只有那些放射性示踪剂摄取与CT上具有弹力纤维瘤特征性表现区域相对应的离散病变才被视为阳性。
总共18/75（24.0%）的患者在F-DCFPyL PET/CT上有至少一个背部弹力纤维瘤的证据。其中8例（44.4%）患者有单侧病变，均为右侧。检测到的病变最大直径中位数为2.3厘米（范围：1.3 - 8.4厘米），与胸壁垂直的厚度中位数为0.9厘米（范围：0.6 - 2.5厘米）。检测到的病变最大标准化摄取值中位数为1.4（范围：1.1 - 2.4），校正去脂体重后的最大标准化摄取值中位数为1.1（范围：0.8 - 1.7）。
本研究首次报告了背部弹力纤维瘤摄取PSMA靶向PET放射性示踪剂的情况。这些良性病变中的放射性示踪剂摄取不应被错误地误认为是转移性PCa的部位。
